Ziconotide
Prialt · Cone Snail Toxin Peptide
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
Ziconotide is FDA approved (Prialt, December 28, 2004) and EMA authorised (February 21, 2005) for intrathecal management of severe refractory chronic pain, supported by three pivotal randomized double-blind placebo-controlled trials (Staats 2004 JAMA in cancer/AIDS pain; Wallace 2006 in nonmalignant pain; Rauck 2006 '301' slow-titration study, n=220, VASPI improvement 14.7% vs 7.2% placebo, P=0.036) and by later meta-analyses (Brookes 2017 pooled responder OR 2.77, 95% CI 1.37 to 5.59). The efficacy signal is statistically significant but modest and the safety burden is high, so the approved intrathecal use grades grade 4 (strong multi-RCT and regulatory), not grade 5 overwhelming consensus.
- FDA
- FDA approved December 28, 2004 (Prialt, intrathecal infusion) with boxed warning for severe psychiatric and neurological adverse effects
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Boxed warning for severe psychiatric symptoms and neurological impairment; contraindicated with prior psychosis; requires an intrathecal pump and specialist management.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Ziconotide. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
An FDA-approved pain medication derived from cone-snail venom, delivered only intrathecally (into the spinal cord). Powerful relief for refractory chronic pain.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
- Severe, refractory chronic pain (Prialt)
- FDA-approved in 2004 for severe chronic pain in patients for whom spinal-fluid (intrathecal) therapy is warranted and who are intolerant of or unresponsive to other treatments, including intrathecal morphine. It is reserved as a last-resort option for the most intractable pain, including cancer pain.
How it works
Ziconotide blocks pain by a route nothing else uses. Pain signals travel up the spinal cord when nerve endings release pain-signaling chemicals, and that release depends on a specific gate, the N-type calcium channel, on those pain neurons. Ziconotide plugs that gate, stopping the release of pain transmitters so the signal never reaches the brain. Because it works on this channel rather than on opioid receptors, it relieves pain that opioids cannot, and it does so without the tolerance or addiction that opioids bring.
Ziconotide is a synthetic 25-amino-acid peptide, tightly folded and stabilized by three disulfide bridges, identical to a component of the venom of the fish-hunting cone snail Conus magus, the conotoxin known as omega-MVIIA. Cone snails use it to paralyze prey. Sold as Prialt, it must be delivered directly into the spinal fluid rather than swallowed or injected into the bloodstream.
- Type
- Cone-snail-venom peptide
- Action
- N-type calcium channel blocker
- Class
- Non-opioid
- Addiction
- None
- Delivery
- Intrathecal only
- Approved
- 2004 (Prialt)
A Cone Snail’s Venom, For Pain Opioids Can’t Reach
Ziconotide is one of the more remarkable drugs in this library: a sea-snail venom turned into a painkiller. It is the synthetic copy of a toxin the cone snail Conus magus uses to immobilize fish, and it is the only approved drug that blocks the N-type calcium channel, which gives it a mechanism unlike every other analgesic, opioids included. That matters most for the hardest cases: it relieves severe, intractable pain, from cancer and other causes, even when morphine has failed, and crucially it produces no tolerance, no addiction and no respiratory depression, a meaningful distinction in the shadow of the opioid crisis. The honest cost is in how hard it is to use. It works only when infused directly into the spinal fluid through an implanted pump, because other routes destroy it or drop blood pressure dangerously, and it has a narrow safety margin with frequent serious nervous-system and psychiatric side effects, plus the infection risks of an implanted catheter. It is a last-resort drug, powerful but difficult.
Safety in detail
Narrow specialist use only. Delivered solely by intrathecal infusion pump for severe refractory pain when systemic analgesics and intrathecal morphine have failed. The FDA boxed warning flags severe psychiatric symptoms (including hallucinations, mood change, cognitive impairment) and neurological impairment; dizziness, confusion, ataxia, abnormal gait and memory impairment are common. Slow titration to a low dose improves tolerability. Contraindicated in patients with a preexisting history of psychosis. It is not a research peptide, wellness product, or self-administered agent.
- It has a narrow therapeutic window and frequently causes serious nervous-system effects, including dizziness, confusion, unsteady gait, memory and vision disturbances and nausea.
- It carries a boxed warning for severe psychiatric and neurological impairment, including cognitive impairment, hallucinations, mood changes and suicidality.
- Its intrathecal delivery brings infection risks, including meningitis, which can be fatal.
- It does, however, cause no tolerance, no addiction and no respiratory depression, key advantages over opioids.
- It is reserved for severe refractory pain under pain specialists.
Children and teenagers
Ziconotide is not established or approved for pediatric use. It is an intrathecal last-resort drug with a difficult safety profile, reserved for severe refractory pain under specialists, and any pediatric severe-pain management belongs strictly with pediatric pain and palliative specialists. There is no routine pediatric use.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Ziconotide’s economy is a niche but legitimate one: a specialty intrathecal pain drug sold as Prialt and used within the implanted-pump and pain-management ecosystem. It is high-value per patient but used in a small population, and its commercial story is straightforward approved medicine rather than consumer marketing.
How we got here
Ziconotide is the synthetic form of omega-conotoxin MVIIA, a peptide isolated from the venom of the marine cone snail Conus magus. Developed as SNX-111 by Neurex and later Elan, it passed to Jazz Pharmaceuticals and gained FDA approval in December 2004 as an intrathecal analgesic for severe chronic pain, marketed as Prialt.
Calcium-channel-blocking venom peptides were isolated from cone snails in 1991, and the compound that became ziconotide was first explored for stroke and brain injury before chronic-pain trials began in the mid-1990s. Three Phase 3 trials supported approval, and the FDA cleared ziconotide as Prialt in 2004, with European approval following in 2005. It became a niche intrathecal pain option and a landmark example of venom-derived drug discovery.
- 1991Calcium-channel-blocking conotoxins are isolated from cone snails.
- 1990sThe compound is studied first for stroke, then for chronic pain.
- pre-2004Three Phase 3 trials show benefit in severe refractory pain.
- 2004-2005The FDA and European regulators approve it as Prialt.
- ongoingIt remains a niche, last-resort intrathecal pain drug.
The numbers behind the grade
- Type
- Cone-snail-venom peptide
- Action
- N-type channel blocker
- Class
- Non-opioid
- Delivery
- Intrathecal
- Approved
- 2004
- Addiction
- None
The people taking it
The cone-snail-venom painkiller, the only N-type calcium channel blocker, a non-opioid intrathecal drug for the most severe, treatment-refractory pain.
Ziconotide’s users are patients with severe, intractable chronic pain, often from cancer or refractory neuropathic conditions, who have failed other therapies including intrathecal morphine. They are managed by pain specialists using implanted pumps, a small and severely affected population.
Approved for severe refractory chronic pain, delivered intrathecally as a last-resort, non-opioid option where other therapies and intrathecal morphine fail. A niche specialty drug.
Set against the alternatives
The central comparison is to opioids and intrathecal morphine: opioids bring tolerance, addiction and respiratory depression and can fail in refractory pain, while ziconotide is non-opioid and non-addictive and works where morphine fails, though it carries its own nervous-system and psychiatric risks and a harder delivery, and it can reduce opioid needs. Against gabapentin and pregabalin, which act on a different calcium-channel type and are oral and milder, ziconotide is the only N-type blocker and is reserved for severe pain. And against exenatide, its venom-derived sibling drawn from Gila monster venom, it shows the same theme of venom becoming medicine. Its strength is a unique, non-addictive mechanism; its trade-off is a difficult, invasive delivery.
What we do not know
- Whether better-tolerated or non-intrathecal N-type blockers can be developed.
- Its optimal place relative to intrathecal morphine.
- How best to manage its narrow therapeutic window and side effects.
- The broader promise of cone-snail conotoxins as drug leads.
What could change
Better-tolerated blockersEfforts continue to develop N-type blockers that are easier and safer to use.Conotoxin discoveryCone-snail venoms remain a rich, largely untapped source of drug leads.Opioid alternativeIts non-addictive analgesia is notable amid the opioid crisis.Side-effect managementRefining delivery and dosing to limit its burden remains active.
Legal status
Ziconotide is FDA-approved (2004) for severe refractory chronic pain delivered intrathecally, and it requires an implanted spinal-fluid pump and pain-specialist management. It is reserved as a last resort and is not a consumer or gray-market compound.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Ziconotide is a specialty pain-management drug delivered through an implanted intrathecal pump and administered by pain specialists, not a consumer or self-administered compound. The only route is specialist care, and it is reserved for severe refractory pain.
Ziconotide is an expensive specialty drug, compounded with the cost of the implanted pump and procedure, and it is reserved for severe cases where other options have failed.
Ziconotide comes from regulated pharmaceutical manufacturing as a specialty intrathecal drug with full quality assurance, administered via implanted pump.
Specialty pharmaceuticalZiconotide is supplied as a regulated intrathecal drug through specialty channels.Implanted-pump infrastructureIt depends on implanted intrathecal pumps managed by pain specialists.Pain-management centersIt is administered in specialized clinical settings.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Ziconotide.
Nothing outstanding on this one.
Sources
FDA approved Prialt (ziconotide) December 28, 2004 for intrathecal management of severe chronic pain refractory to other treatment, with boxed warning for psychiatric and neurological effects and contraindication in prior psychosis
FDA Prescribing Information (Prialt), accessdata.fda.gov drugsatfda label 021060s012
PRIALT (ziconotide acetate) label including boxed warning for severe psychiatric symptoms and neurological impairment, intrathecal-only indication, and psychosis contraindication
Prialt authorised in the EU since 21 February 2005 for severe chronic pain requiring intrathecal analgesia; ziconotide is a synthetic omega-conopeptide from cone snail venom given by slow intrathecal infusion
EMA orphan designation (EU/3/01/048) for treatment of chronic pain requiring intraspinal analgesia, designated 9 July 2001
Pivotal RCT: intrathecal ziconotide provided clinically and statistically significant analgesia in refractory cancer or AIDS pain (Staats et al., JAMA 2004)
Pivotal '301' RCT (n=220): slow-titration intrathecal ziconotide gave VASPI mean improvement 14.7% vs 7.2% placebo (P=0.036); common AEs dizziness, confusion, ataxia, abnormal gait, memory impairment (Rauck et al., J Pain Symptom Manage 2006)
Systematic review and meta-analysis of ziconotide monotherapy RCTs: pooled responder odds ratio 2.77 (95% CI 1.37 to 5.59) favouring ziconotide, with frequent serious adverse events and methodological caveats
Brookes ME et al., Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials (PMC)
Meta-analysis and systematic review of the Cav2.2 blocker ziconotide: significant pain reduction versus placebo (mean difference -22.54, 95% CI -36.70 to -8.38, P=0.002) with high heterogeneity; adverse events 94.9% vs 76.9% placebo and serious AEs about 17.85%
Review of ziconotide pharmacology and clinical use confirming N-type (Cav2.2) calcium channel block, intrathecal-only delivery, and narrow therapeutic index
Ziconotide: a review of its pharmacology and use in the treatment of pain (PMC)
Payer clinical policy confirming FDA-approved indication limited to intrathecal therapy for severe chronic pain in patients intolerant of or refractory to other treatment including intrathecal morphine
The studies that matter
Conotoxin discovery1991
Venom peptides that block calcium channels were isolated from cone snails, leading to the development of what became ziconotide.
Unique mechanismestablished
Ziconotide selectively blocks neuronal N-type calcium channels, halting release of pain transmitters, a mechanism distinct from all other analgesics including opioids.
Phase 3 trialspre-2004
Three Phase 3 trials in more than 1,200 patients showed ziconotide reduced severe pain versus placebo, including refractory cancer pain.
No tolerance or addictionestablished
Unlike opioids, ziconotide produces no tolerance and no addiction even with prolonged use.
Approval2004-2005
The FDA approved ziconotide in 2004 and the European Medicines Agency in 2005 for severe refractory chronic pain.